Literature DB >> 21236717

Metformin and digestive disorders.

M Bouchoucha1, B Uzzan, R Cohen.   

Abstract

Digestive disorders (diarrhoea, vomiting) represent the most common metformin side-effects (around 30%) with this first-line drug treatment for type 2 diabetes. In healthy individuals, metformin affects glucose, vitamin B12 and the digestive uptake of bile salts. In the colon, it acts locally by modifying glucose cell metabolism. Different pathophysiological hypotheses have been proposed to explain the metformin-induced diarrhoea and vomiting, which can sometimes cause the patient to stop an effective treatment. These theories include stimulation of intestinal secretion of serotonin, changes in incretin and glucose metabolism, and bile-salt malabsorption. However, none of these hypotheses can be considered an adequate pathophysiological explanation of metformin digestive side-effects. In addition, there is a lack of experimental data to explain these highly patient-dependent adverse effects.
Copyright © 2010 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21236717     DOI: 10.1016/j.diabet.2010.11.002

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  42 in total

Review 1.  Metformin: clinical use in type 2 diabetes.

Authors:  Elizabeth Sanchez-Rangel; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2017-08-02       Impact factor: 10.122

Review 2.  Gastrointestinal Complications of Obesity.

Authors:  Michael Camilleri; Harmeet Malhi; Andres Acosta
Journal:  Gastroenterology       Date:  2017-02-10       Impact factor: 22.682

3.  The effect of lansoprazole, an OCT inhibitor, on metformin pharmacokinetics in healthy subjects.

Authors:  Yi Ding; YanYan Jia; Ying Song; ChengTao Lu; YuWen Li; MinChun Chen; MingMing Wang; AiDong Wen
Journal:  Eur J Clin Pharmacol       Date:  2013-10-30       Impact factor: 2.953

Review 4.  Advances in understanding of bile acid diarrhea.

Authors:  Michael Camilleri
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2013-11-25       Impact factor: 3.869

Review 5.  Gastrointestinal morbidity in obesity.

Authors:  Andres Acosta; Michael Camilleri
Journal:  Ann N Y Acad Sci       Date:  2014-03-06       Impact factor: 5.691

Review 6.  Drug-induced gastrointestinal disorders.

Authors:  H L Philpott; S Nandurkar; J Lubel; P R Gibson
Journal:  Frontline Gastroenterol       Date:  2013-06-19

7.  Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels.

Authors:  Jeffrey H Burton; Matthew Johnson; Jolene Johnson; Daniel S Hsia; Frank L Greenway; Mark L Heiman
Journal:  J Diabetes Sci Technol       Date:  2015-03-23

8.  Prediction and validation of enzyme and transporter off-targets for metformin.

Authors:  Sook Wah Yee; Lawrence Lin; Matthew Merski; Michael J Keiser; Aakash Gupta; Youcai Zhang; Huan-Chieh Chien; Brian K Shoichet; Kathleen M Giacomini
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-09-03       Impact factor: 2.745

9.  Risk of Metformin-Associated Lactic Acidosis (MALA) in Patients After Gastric Bypass Surgery.

Authors:  Laura N Deden; Edo O Aarts; Stephanie C W Aelfers; Marcel M G J van Borren; Ignace M C Janssen; Frits J Berends; Hans de Boer
Journal:  Obes Surg       Date:  2018-04       Impact factor: 4.129

Review 10.  Targeting hepatic glucose metabolism in the treatment of type 2 diabetes.

Authors:  Amy K Rines; Kfir Sharabi; Clint D J Tavares; Pere Puigserver
Journal:  Nat Rev Drug Discov       Date:  2016-08-12       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.